Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07488156 for Schizophrenia Disorder, Schizoaffective Disorder, Psychosis is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder 34
Clinical Trial NCT07488156 is an interventional study for Schizophrenia Disorder, Schizoaffective Disorder, Psychosis and is currently not yet recruiting. Enrollment is planned to begin on 1 March 2026 and continue until the study accrues 34 participants. Led by Louisiana State University Health Sciences Center in New Orleans, this study is expected to complete by 1 January 2028. The latest data from ClinicalTrials.gov was last updated on 23 March 2026.
Brief Summary
The Impact of Health Literacy on the Attitudes toward Pharmacological Treatment in Patients with Schizophrenia Spectrum Disorder
This interventional study is aimed at:
- assessing and improving the health literacy and
- assessing the attitude towards treatment of patients with schizophrenia spectrum disorders while they are admitted to the inpatient psychiatric unit.
Detailed Description
The study will take place at University Medical Center in New Orleans, LA and will include 34 patients with a schizophrenia spectrum disorder diagnosis who are admitted to the psychiatric unit. Participants will take tests to assess their knowledge of SSD before and after receiving educational materials during their hospitalization. They will also receive questionnaires assessing their attitudes toward treatment befo...Show More
Official Title
The Impact of Health Literacy on the Attitudes Toward Pharmacological Treatment in Patients With Schizophrenia Spectrum Disorder
Conditions
Schizophrenia DisorderSchizoaffective DisorderPsychosisPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- 8277
- R076477SCH4075 (Other Grant/Funding Number) (Janssen Scientific Affairs, LLC)
NCT ID Number
Start Date (Actual)
2026-03-01
Last Update Posted
2026-03-23
Completion Date (Estimated)
2028-01-01
Enrollment (Estimated)
34
Study Type
Interventional
PHASE
N/A
Status
Not yet recruiting
Keywords
Educational interventions
Schizophrenia
Schizophrenia spectrum disorders
Health literacy
Schizophrenia
Schizophrenia spectrum disorders
Health literacy
Primary Purpose
Other
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalPatients admitted to the inpatient psychiatric unit with a schizophrenia spectrum disorder diagnosis Patients will be exposed to educational materials in the form of a pamphlet and a video | Educational sessions Patients will be given an educational pamphlet with information about schizophrenia spectrum disorders, including prognosis and management options. Following this, they will be allowed to ask the doctor any questions they have pertaining to schizophrenia spectrum disorder. In the second educational session, patients will watch a video containing information about schizophrenia spectrum disorders. Following this, they...Show More |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Post-intervention KAST (Knowledge About Schizophrenia Test) scores | This includes an 18-item multiple choice test, with only one correct answer for each item. Scores range from 0 to 100%. Higher scores indicate a higher level of knowledge. | This will be collected on Day 5 of the study, after the participant has completed both educational sessions. |
Post-intervention ATT (Attitudes Toward Treatment) scores | This test includes a total of 20 questions, each ranging from 0 to 10 points. Total score ranges from 0 to 200 points. Higher scores indicate a more favorable attitude towards medications. | This will be collected on Day 5 of the study, after the participant has completed both educational sessions. |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
MARS (Medication Adherence Rating Scale) scores | This is a 10-item questionnaire with only yes and no answer choices. Participants will be given 0 points for answers that represent poor adherence and they will be given 10 points for answers that represent good adherence. Scores will range from 0 to 100 points, with higher scores indicating more adherence. | This questionnaire will be given on a monthly basis in the follow up period, for a total of 12 months. |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Patients admitted to the University Medical Center-New Orleans (UMCNO) inpatient behavioral health unit ages 18 and older with a new or previous diagnosis of schizophrenia spectrum disorder outside of substance use disorders
- Patients must be proficient in English.
- Patients must have a government issued social security number (required for reimbursement through the university).
- Patients at UMCNO that are ages 17 or younger
- Patients with SSD and concomitant intellectual disability, as evidenced by prior documented history on chart review or patients suspected to have intellectual disability or impairment based on clinical interactions
- Patients with concomitant substance use and documentation of psychosis being resolved after a period of washout and without the use of psychotropic medications
- Patients unable to complete health literacy assessments, attitude towards treatment assessments, and IQ testing due to severity of symptoms during hospitalization
- Patients that are not proficient in English
- Patients that do not have a government issued social security number
Louisiana State University Health Sciences Center in New OrleansJanssen PharmaceuticalsNo contact data.
1 Study Locations in 1 Countries
Louisiana
University Medical Center, New Orleans, Louisiana, 70112, United States
Jaudé Petrie, MD, Contact, 504-702-3000, [email protected]
Jaudé Petrie, MD, Principal Investigator